<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369549</url>
  </required_header>
  <id_info>
    <org_study_id>MPAC-CKD</org_study_id>
    <nct_id>NCT02369549</nct_id>
  </id_info>
  <brief_title>Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease</brief_title>
  <acronym>MPAC-CKD</acronym>
  <official_title>Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Kidney Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An investigator initiated pilot trial: two arm, double blind, placebo controlled, randomized,
      parallel group of approximately 750 patients with chronic kidney disease, and who have
      evidence of overt proteinuria, will be treated with micro-particle curcumin versus placebo
      over 24 weeks from start of the investigational medication date (approximately 6 months) to
      test whether curcumin can slow chronic kidney disease progression in patients. Three 30 mg
      capsules of micro-particle curcumin will be self-administered once daily in the morning to
      determine the the safety and efficacy of curcumin relative to placebo in reducing albuminuria
      and slowing the loss of eGFR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Limiting the progression from CKD to end-stage renal disease is one of the most important
      goals in kidney medicine. The evidence implicating inflammation and fibrosis in that process
      is strong, and there is abundant mechanistic and animal model data to show that curcumin is a
      potent inhibitor of both inflammation and fibrosis. Two preliminary randomized trials in
      human CKD hint at curcumin's enormous therapeutic potential in CKD. The Principal
      Investigator/Sponsor will rigorously test this potential in a broadly selected sample of up
      to 750 patients with CKD. Compared to previous studies, this study's results will be
      generalizable across other etiologies of CKD and with a larger sample size; this study will
      provide more precise estimates of curcumin's benefits and risks. Also, this study proposes to
      use a new, micro-particle formulation of curcumin that is highly bioavailable. The Principal
      Investigator/Sponsor will assess curcumin's effects on three key markers of kidney health
      that encompass the cardinal functions of the nephron. Positive results from MPAC-CKD will lay
      solid scientific ground-work for a multi-centre trial capable of testing micro-particle
      curcumin's effect of the most meaningful outcomes: death and the development of end-stage
      renal disease.

      To ensure that this study will have the necessary adherence and tolerability data, up to 750
      patients with proteinuric CKD will be randomly assigned to 90 mg per day of micro-particle
      curcumin or matching placebo, for a total of 24 weeks (approximately 6 months). In the last
      few years, new formulations of curcumin have been shown to substantially augment absorption
      by improving its aqueous solubility. The micro-particle formulation of curcumin is one of
      these new formulations and is the only curcumin delivery system proven to increase
      bioavailability. Compared to traditional curcumin, micro-particle curcumin achieves total
      serum concentrations that are 27 fold higher. In this study, micro-particle curcumin will
      allow the study team to administer the equivalent of 3000 mg of traditional curcumin (which
      would require six 500 mg capsules daily), in a single 90 mg capsule. In addition, as opposed
      to traditional curcumin, there is no requirement to take micro-particle curcumin on a full
      stomach. The Investigator/Sponsor has selected a dose equivalent to 3 grams per day of
      curcumin because this is within the range of doses proven safe and effective and it will
      minimize pill burden by allowing the full daily dose to be achieved by three small 30 mg
      capsules daily In rare cases, curcumin has been reported to cause minor nausea, headache,
      diarrhea, yellow stool, and temporary giddiness. All unexpected reactions reported in
      previous studies were easily managed and happened at higher doses than what will be used in
      MPAC-CKD.

      This study will assess two primary outcomes: the 6-month change in albuminuria, and the
      6-month change in eGFR.

      Secondary outcomes will include health-related quality of life, glycemic control among
      patients with diabetes mellitus, and a composite of progressive CKD, ESRD and death. The
      investigators will also measure serum curcumin levels in the first 30 randomized
      participants, who will have a 4.5 ml blood sample taken at the 12 week (3 month) visit. This
      sample will be processed and stored at -80 degrees C. for batch testing for plasma
      micro-particle curcumin concentrations.

      The investigators will conduct a subgroup analysis based on participants 2-year risk of
      requiring dialysis using the validated Kidney Failure Risk Equation to group patients into a
      high risk group (10% or greater risk of dialysis within 2 years) and low risk group (&lt;10%
      risk within 2 years).

      Medical history, lab values and vitals will be collected and/or updated at each in-person
      visit. Each participant will be provided with instructions and study schedule. Participants
      with diabetes mellitus will be given a home glucose log-book.

      Protocol compliance will be tested through pill counts and interviews at each follow-up
      visit. Side effects will be assessed using standardized case report forms at each visit.
      Participants will be contacted by telephone one week into the trial and then once every 4
      weeks (monthly) for 28 weeks (approximately 7 months) for safety monitoring and reporting and
      to reinforce importance of compliance. In-person visits will occur at 12 and 24 weeks
      (approximately 3 and 6 months) after randomization and the start of the investigational
      medication, at which time investigational medication will be counted and supply replenished.
      First morning at-home urine specimens will be collected at baseline and again arranged at the
      in-person visits at 12 and 24 weeks (approximately 3 and 6 months). Participants will also be
      encouraged to report any events they may experience directly to the coordinator(s) and/or PI.

      Participants who withdraw consent to continue treatments, will be encouraged to undergo the
      planned assessments. Withdrawal at the request of investigators or medical personnel may
      include, but are not limited to:

        1. Symptoms are deemed to be potentially related to the sue of the investigational
           medication;

        2. New diagnosis of exclusion criteria;

        3. Inter-current illness not related to the use of the investigational Natural Health
           Product (NHP) medication;

        4. Unacceptable side effects;

        5. Death;

        6. Improved health status.

      Estimated time to complete recruitment: Averaging 136 weeks, approximately 34 months.

      Long-term outcomes will be tracked using administrative data housed at The Institute for
      Clinical Evaluative Sciences (ICES), an independent research facility in Toronto, Ontario.
      ICES works with the Ontario Ministry of Health and Long-Term Care to study the impact of
      health care and diseases in Ontario.

      A panel of external experts and study investigators will comprise the Steering Committee and
      will ensure the integrity of the study. They will be responsible for reviewing and acting
      upon the recommendations of the Data Safety Monitoring Board, amendments to the protocol,
      oversight of publication and dissemination of study results.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in albuminuria from baseline to 24 week (6 month)</measure>
    <time_frame>Baseline and 24 weeks (6 months)</time_frame>
    <description>Albuminuria will be measured using urinary albumin-to-creatinine ratio from first morning urine samples. At each visit (pre-randomization, and 3- and 6-months post-randomization), urinary albumin-to-creatinine ratio is measured on two consecutive days and the average of the two values will be computed. The average of the two values will be log-transformed using the natural logarithm. Albuminuria is the cardinal manifestation of a malfunctioning filtration barrier and the spillage of albumin into renal tubules is thought to be toxic to tubular cells, resulting in further kidney damage. Therefore, in the current understanding, albuminuria is both a marker and a mediator of kidney damage. Reduction of albuminuria has repeatedly been associated with improved renal outcomes. Leaders in the field of nephrology recommend that albuminuria be used as a valuable predictor of response to therapy for the prevention of kidney failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Estimated Glomerular Filtration rate (eGFR) from baseline to 24 weeks (6 months)</measure>
    <time_frame>Baseline and 24 weeks (6 months)</time_frame>
    <description>eGFR will be calculated using the CKD-EPI formula. The investigators will estimate the between-group difference in change in eGFR (6-month eGFR minus baseline eGFR), expressed in mL/min per 1.73m2, using linear regression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control among participants with diabetes mellitus</measure>
    <time_frame>Baseline and 24 week (6 months)</time_frame>
    <description>The investigators will summarize the percentage of glycated hemoglobin pre-randomization and 6-months post-randomization and will present the between-group difference in change in percentage of glycated hemoglobin (6-month value minus pre-randomization value) among patients with diabetes mellitus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure composite</measure>
    <time_frame>24 week (6 months)</time_frame>
    <description>The investigators will report on the outcome of progressive CKD, ESRD, and death, first as a composite outcome, and then as separate components. ESRD will be defined as an eGFR &lt;15 mL/min/1.73 m2 or the initiation of renal replacement therapy, which includes chronic dialysis or transplantation; progressive CKD will be defined as an eGFR loss of â‰¥ 30% (anytime during follow-up from the pre-randomization baseline value) or ESRD. Less than 10% of participants will be expected to experience these outcomes by 6 months. The focus of this analysis is to document any trends to inform the expected event rate for future studies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life (physical composite summary)</measure>
    <time_frame>Baseline and 24 week (6 months)</time_frame>
    <description>Health-related quality of life scores will be determined by the RAND version of the 36-Item Short Form Health Survey (SF-36) administered pre-randomization and at 3-months and 6-months post-randomization. The physical composite summary (PCS) score of the SF-36 will be examined. The between-group difference in change in score, 6-month value minus pre-randomization value, will be reported with 95% CIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life (mental composite summary)</measure>
    <time_frame>Baseline and 24 week (6 months)</time_frame>
    <description>Health-related quality of life scores will be determined by the RAND version of the 36-Item Short Form Health Survey (SF-36) administered pre-randomization and at 3-months and 6-months post-randomization. The mental composite summary (MCS) score of the SF-36 will be examined. The between-group difference in change in score, 6-month value minus pre-randomization value, will be reported with 95% CIs.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum curcumin levels</measure>
    <time_frame>12 weeks (3 months)</time_frame>
    <description>To confirm our micro-particle curcumin was bioavailable, and to strengthen any relationship between micro-particle curcumin and any outcomes identified, serum levels of curcumin and its major metabolites will be measured in the first 30 participants 3 months after randomization (including patients taking micro-particle curcumin and those taking placebo). Serum curcumin and its major metabolites will be summarized in the first 30 participants randomized, by group. The between-group difference in average serum curcumin levels measured 3-months post-randomization will be reported with the 95% CI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney failure risk subgroup</measure>
    <time_frame>Baseline and 24 week (6 months)</time_frame>
    <description>The investigators will conduct an exploratory subgroup analysis based on a higher or lower estimated risk of kidney failure, using the kidney failure risk equation. Participants with a 2-year risk of ESRD less than 10% will be classified as lower risk, and patients with a risk of 10% or more will be classified as higher risk.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">518</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Micro-particle curcumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three 30 mg capsules once daily, self-administered for 6 months.
Curcumin is a nutraceutical, which are products isolated or purified from foods. The rhizomes of the plant Curcuma longa produces turmeric, a spice commonly used in Indian cuisine. Turmeric is comprised of three curcuminoids, of which curcumin is the most abundant. Curcumin is a polyphenol molecule that has been investigated for anti-inflammatory and anti-neoplastic properties since the 1970s.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three 30 mg capsules taken once daily, self-administered for 6 months.
Placebo capsules are identical to the curcumin capsules in color, taste, smell, size and shape.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micro-particle Curcumin</intervention_name>
    <description>as described in Arm</description>
    <arm_group_label>Micro-particle curcumin</arm_group_label>
    <other_name>Theracumin-Pro 300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Looks, smells, tastes and feels exactly like the Curcumin capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. eGFR between 15 and 60 ml/min/1.73 m2;

          2. Albuminuria, defined by the most recent measurement within the prior 3 months showing
             either: a) 24-hour urine collection with a minimum of 300 mg of protein, OR b) urinary
             albumin to creatinine ratio equivalent to a daily excretion of albumin of at least 300
             mg;

          3. If diabetic, is able and willing to take and record glucose levels at home;

          4. If receiving and ACE inhibitor or angiotension II receptor blocker (ARB), the dosage
             must be stable for 2 weeks prior to screening. Patients not taking and ACE or ARB must
             have a documented medical contraindication (e.g. hyperkalemia, hypotension);

          5. Willing and able to give written informed consent for participation and provide
             consent for access to medical data according to local data protection laws and
             regulations.

        Exclusion Criteria:

          1. Life expectancy &lt; 1 year;

          2. Known allergy to turmeric or its derivatives (ginger, curry, cumin, or cardamom);

          3. Known allergy to ingredients of the study product or placebo (microcrystalline
             cellulose, vegetarian capsule, vegetable grade magnesium stearate, silica;

          4. Pregnant or breastfeeding;

          5. Women of child-bearing potential who are not either surgically sterile or not
             postmenopausal for at least 1 year;

          6. Plans for transplantation during the study period;

          7. Receipt of hemodialysis or peritoneal dialysis in the past 3 months;

          8. Active peptic ulcer disease;

          9. Hepatobiliary disease in the past 4 weeks;

         10. Evidence of acute kidney injury (&gt;50% increase in serum creatinine in the past 30
             days);

         11. History of significant bleeding (GI or retroperitoneal bleed requiring transfusion, or
             any intracranial hemorrhage in the past 6 months);

         12. Ongoing use of warfarin;

         13. Ongoing treatment with cyclophosphamide, camptothecin, mechlorethamine or doxorubicin;

         14. Ongoing use of anti-psychotic medication including haloperidol, aripiprazole,
             risperidone, ziprasidone, pimozide, and quetiapine;

         15. Previous participation in MPAC-CKD;

         16. Current participation on another investigational medication trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Weir, Nephrologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>LHSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Population Health Research Institute</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidney Clinical Care Unit</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Matthew Weir</investigator_full_name>
    <investigator_title>Nephrologist, MD, FRCPC, MSc</investigator_title>
  </responsible_party>
  <keyword>Chronic Kidney Disease (CKD)</keyword>
  <keyword>Micro-particle curcumin</keyword>
  <keyword>Albuminuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 29, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02369549/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

